Because Mesoblast is a global leader in cell therapy and research. Any activity in this space and progress especially commentary out of the fda and approvals in this space must be considered when looking at the progress of the overall sector of regenerative medicine.
To ignore the activity and commentary in this space for its therapeudic benefits wouldn't be prudent.
I remain positive on this sector and on Mesoblast's leading involvement in this space.
Cell Therapy News/Articles, page-9
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.77 |
Change
0.030(1.72%) |
Mkt cap ! $1.113B | |||
| Open | High | Low | Value | Volume |
| $1.75 | $1.79 | $1.73 | $4.141M | 2.353M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 6673 | $1.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.78 | 34437 | 3 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
